ReviewJournal of cellular and molecular medicine2026
Integrating Flow Cytometry in the Diagnostic Work of HIV-Associated Hodgkin's Lymphomas.
Review in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Hodgkin lymphoma (HL) is prevalent worldwide and typically presents symptoms like sudden pain, swelling, and weight loss. Classical HL (cHL) is largely treatable with modern risk-adapted and response-based therapy. cHL represents one of the most common malignancies occurring during the course of evolution in patients living with HIV. The present manuscript aimed to present the diagnostic work-up with an emphasis on flow cytometry in patients with HIV-associated lymphoma, of important clinical benefit both in the HIV-endemic setting as well as in state-of-the-art pathology departments. Three clinical cases of HIV patients, including HIV-associated cHL, are presented in the chapter dedicated to HIV-induced lymphomas diagnosed by FC, as Supporting Information, to support the particularities of the abundance of clonal B-cell populations among different types of HIV-related lymphomas. This adds to the proof-of-concept that the specific antibody panel design may help practitioners in discriminating among similar subtypes of HIV-associated lymphomas. Recent data emphasise the importance of FC detection of cHL rapidly and effectively, adding diagnostic value to these small biopsies. FC is an important tool for clinical decision-making in the management of HL patients, providing a noninvasive and accurate biomarker evaluation. For these considerations, we can conclude that FC is a very useful research tool, and the clinical cases presented in this paper indicate their importance in the rapid diagnosis of cHL as well.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.